TG Therapeutics TGTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $700.35M+13.6% | $616.29M+15.9% | $531.9M+17.1% | $454.07M+17.5% | $386.39M+17.4% | ||
| $118.68M+17.8% | $100.71M+29.2% | $77.97M+31.7% | $59.22M+21.9% | $48.59M+26.2% | ||
| $581.67M+12.8% | $515.57M+13.6% | $453.93M+15.0% | $394.85M+16.9% | $337.8M+16.3% | ||
| 83.1%-0.6pp | 83.7%-1.7pp | 85.3%-1.6pp | 87%-0.5pp | 87.4%-0.9pp | ||
| $162.25M+1.3% | $160.22M+12.1% | $142.9M+17.0% | $122.16M+13.2% | $107.93M+14.5% | ||
| $269.92M+16.3% | $232.03M+11.4% | $208.25M+11.5% | $186.85M+9.9% | $170.05M+10.2% | ||
| $218.43M+18.7% | $183.98M+12.6% | $163.43M+12.2% | $145.63M+8.7% | $133.92M+8.9% | ||
| $550.85M+11.7% | $492.96M+14.9% | $429.12M+16.5% | $368.22M+12.8% | $326.57M+13.8% | ||
| $149.5M+21.2% | $123.32M+20.0% | $102.78M+19.7% | $85.85M+43.5% | $59.82M+42.7% | ||
| 21.3%+1.3pp | 20%+0.7pp | 19.3%+0.4pp | 18.9%+3.4pp | 15.5%+2.7pp | ||
| $27.64M+3.4% | $26.73M-1.9% | $27.26M-13.1% | $31.37M+9.6% | $28.63M+18.5% | ||
| -$27.21M-70.8% | -$15.93M-6.0% | -$15.03M+23.9% | -$19.74M-9.2% | -$18.08M-10.7% | ||
| —— | —— | —— | —— | -$3.46M+25.0% | ||
| $122.29M+13.9% | $107.39M+22.4% | $87.75M+32.7% | $66.11M+58.4% | $41.74M+63.1% | ||
| -$361.67M0.0% | -$361.85M-0.6% | -$359.72M-6,466% | $5.65M+118% | $2.59M+17.1% | ||
| $461.9M+3.3% | $447.18M-0.1% | $447.47M+640% | $60.46M+54.4% | $39.15M+67.4% | ||
| 66%-6.6pp | 72.6%-11.6pp | 84.1%+70.8pp | 13.3%+3.2pp | 10.1%+3.0pp | ||
| $2.87+3.2% | $2.780.0% | $2.78+651% | $0.37+54.2% | $0.24+71.4% | ||
| $3.22+3.5% | $3.11+1.3% | $3.07+649% | $0.41+51.9% | $0.27+58.8% | ||
| 645M-0.4% | 647.7M+0.2% | 646.7M0.0% | 646.4M+0.5% | 643.2M+2.6% | ||
| 580.9M-0.4% | 583.2M-0.2% | 584.2M+0.1% | 583.8M+0.3% | 581.8M+0.1% | ||
| $18.16M+9.3% | $16.62M+2.9% | $16.14M+16.7% | $13.84M+14.9% | $12.04M+7.9% | ||
| $51.49M+7.1% | $48.05M+7.2% | $44.82M+8.7% | $41.22M+14.1% | $36.14M+15.1% | ||
| $9.58M-11.3% | $10.79M-11.7% | $12.23M+5.2% | $11.63M+10.3% | $10.55M+34.8% | ||
| $144.09M+0.3% | $143.6M+13.3% | $126.75M+17.0% | $108.32M+13.0% | $95.89M+15.4% | ||
| $700.35M+13.6% | $616.29M+15.9% | $531.9M+17.1% | $454.07M+17.5% | $386.39M+17.4% | ||
| $149.5M+21.2% | $123.32M+20.0% | $102.78M+19.7% | $85.85M+43.5% | $59.82M+42.7% | ||
| $149.58M+21.2% | $123.38M+20.0% | $102.83M+19.7% | $85.89M+43.5% | $59.87M+42.6% | ||
| $149.58M+21.2% | $123.38M+20.0% | $102.83M+19.7% | $85.89M+43.5% | $59.87M+42.6% | ||
| 21.4%+1.3pp | 20%+0.7pp | 19.3%+0.4pp | 18.9%+3.4pp | 15.5%+2.7pp | ||
| $149.5M+21.2% | $123.32M+20.0% | $102.78M+19.7% | $85.85M+43.5% | $59.82M+42.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is TG Therapeutics's revenue?
- TG Therapeutics (TGTX) generated $700.3M in revenue over the trailing twelve months, up 81.3% year over year.
- Is TG Therapeutics profitable?
- TG Therapeutics reported $461.9M in net income over the trailing twelve months, a 66.0% net margin.
- What are TG Therapeutics's profit margins?
- Gross margin is 83.1% and operating margin is 21.3%, with a 66.0% net margin.
- What is TG Therapeutics's earnings per share?
- TG Therapeutics's diluted EPS over the trailing twelve months is $2.87.
- Where does TG Therapeutics's income statement data come from?
- Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
